Though novel treatment approaches and drug discoveries have shifted the treatment paradigms of plasma cell dyscrasias (multiple myeloma (MM), Waldenstrom’s macroglobulinemia (WM), and light chain amyloidosis (AL)) these diseases remain treatable but incurable. Most patient relapses are due to minimal residual disease and drug resistance. Differential diagnoses of AL, MGUS, and MM are sometimes challenging because these conditions share genetic and epigenetic similarities. Unrecognized co-evolution of different disease-causing clones leads to high-risk myeloma, treatment failure and inevitably becomes life-threatening in these malignancies. More intense and personalized approaches are being explored as high-risk myeloma has inferior outcomes.
Understanding and targeting plasma cell neoplasms and precursor conditions are gaining increasing attention because targeted prevention and personalized precision treatment approaches have been shown to lead to better patient outcomes. The goal of this Research Topic is to summarize recent discoveries of precision medicine in PC dyscrasias and discuss their integration and use in the care of patients. Using real patient cases as a starting point, we will translate recent clinical data to optimize therapeutic strategies. Furthermore, in this Research Topic, we review various challenges associated with the use of novel drug combinations. We will also discuss issues related to the evaluation of high-risk diseases, the interpretation of the clinical data, and their successful implementation into the clinical settings.
We welcome submissions that:
- Translate recent clinical data concerning the management of PC dyscrasias to real-world clinical practice
- Assess progression risk from precursor plasma cell conditions
- Evaluate new and emerging therapies for special molecular subtypes of myeloma
- Develop innovative treatment strategies for high-risk and extramedullary myeloma disease
- Using real patient cases to suggest personalized precision approaches for patients with plasma cell neoplasms
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Though novel treatment approaches and drug discoveries have shifted the treatment paradigms of plasma cell dyscrasias (multiple myeloma (MM), Waldenstrom’s macroglobulinemia (WM), and light chain amyloidosis (AL)) these diseases remain treatable but incurable. Most patient relapses are due to minimal residual disease and drug resistance. Differential diagnoses of AL, MGUS, and MM are sometimes challenging because these conditions share genetic and epigenetic similarities. Unrecognized co-evolution of different disease-causing clones leads to high-risk myeloma, treatment failure and inevitably becomes life-threatening in these malignancies. More intense and personalized approaches are being explored as high-risk myeloma has inferior outcomes.
Understanding and targeting plasma cell neoplasms and precursor conditions are gaining increasing attention because targeted prevention and personalized precision treatment approaches have been shown to lead to better patient outcomes. The goal of this Research Topic is to summarize recent discoveries of precision medicine in PC dyscrasias and discuss their integration and use in the care of patients. Using real patient cases as a starting point, we will translate recent clinical data to optimize therapeutic strategies. Furthermore, in this Research Topic, we review various challenges associated with the use of novel drug combinations. We will also discuss issues related to the evaluation of high-risk diseases, the interpretation of the clinical data, and their successful implementation into the clinical settings.
We welcome submissions that:
- Translate recent clinical data concerning the management of PC dyscrasias to real-world clinical practice
- Assess progression risk from precursor plasma cell conditions
- Evaluate new and emerging therapies for special molecular subtypes of myeloma
- Develop innovative treatment strategies for high-risk and extramedullary myeloma disease
- Using real patient cases to suggest personalized precision approaches for patients with plasma cell neoplasms
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
